No Tax Breaks for Drug Ads Act
Latest Action
Referred to the House Committee on Ways and Means.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The No Tax Breaks for Drug Ads Act (H.R. 9021) is a proposed piece of legislation introduced in the 118th Congress that aims to eliminate tax deductions or credits related to advertising expenditures for prescription drugs. The bill was referred to the House Committee on Ways and Means on July 11, 2024, but no further legislative action or detailed text is publicly available. The bill falls under the policy area of taxation and seeks to address the tax treatment of pharmaceutical advertising expenses.
H.R. 9021 proposes to remove tax benefits for prescription drug advertising, but it did not advance beyond committee referral and is currently classified as failed or expired.
- The bill targets tax deductions or credits associated with advertising prescription drugs.
- It was introduced in the House and referred to the House Committee on Ways and Means on July 11, 2024.
- No official summary or full text is publicly available, limiting detailed analysis.
['Potentially the federal government through increased tax revenue if advertising expenses are no longer deductible.', 'Taxpayers indirectly if government revenue increases and is allocated to other priorities.']
['Lack of publicly available full bill text limits clarity on specific provisions and enforcement mechanisms.', 'Implementation challenges could arise in defining and verifying what constitutes drug advertising for tax purposes.', "Potential impacts on pharmaceutical companies' marketing strategies and related economic effects are not detailed."]
The bill was introduced in the House during the 118th Congress and referred to the House Committee on Ways and Means, which oversees tax legislation. The bill did not progress beyond referral and is recorded as failed or expired as of the latest update in November 2024. No summary or detailed legislative history is available to provide further context.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Pharmaceutical companies might reduce spending on direct-to-consumer advertising, potentially affecting consumer awareness of drug options.', 'Changes in tax treatment could influence drug pricing strategies or marketing approaches.', 'Potential shifts in federal tax revenue allocation depending on changes in collected taxes from pharmaceutical companies.']
The lack of an official bill summary and full text limits transparency and public understanding of the bill's specific provisions and potential impacts. Monitoring legislative progress and committee discussions would be necessary for a more comprehensive analysis. Oversight considerations include clarity in defining taxable advertising expenses and ensuring consistent enforcement to avoid disputes or loopholes.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.